C.H. Robinson Worldwide Free cash flow decreased by 78.2% to $65.96M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 36.1%, from $103.18M to $65.96M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 95.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $141.87M | -$87.15M | $68.16M | -$23.97M | $238.52M | $611.52M | $762.19M | $243.17M | $214.52M | $201.03M | $43.23M | -$41.94M | $159.80M | $103.32M | $265.25M | $103.18M | $219.84M | $269.47M | $302.40M | $65.96M |
| QoQ Change | — | -161.4% | +178.2% | -135.2% | >999% | +156.4% | +24.6% | -68.1% | -11.8% | -6.3% | -78.5% | -197.0% | +481.0% | -35.3% | +156.7% | -61.1% | +113.1% | +22.6% | +12.2% | -78.2% |
| YoY Change | — | — | — | — | +68.1% | +801.7% | >999% | >999% | -10.1% | -67.1% | -94.3% | -117.2% | -25.5% | -48.6% | +513.6% | +346.0% | +37.6% | +160.8% | +14.0% | -36.1% |